Secukinumab As A More Efficient Alternative For The Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis Versus Adalimumab And Golimumab From A Peruvian Perspective For Private And Public Health Schemes
Abstract
Authors
A Patino E Karpf